🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology · Phase II

Oncology programs at Phase II — ClinicalTrials.gov pipeline intelligence.

Programs
2,640

Quick answer

Oncology Phase II programs: NovaPharmaNews indexes 2,640 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 23 of 55

  1. Gemcitabine

    ACTUATE THERAPEUTICS, INC.

    Soft Tissue Sarcoma

    phase 2 small molecule terminated

    1 trial

  2. Gemcitabine

    ACTUATE THERAPEUTICS, INC.

    Sarcoma

    phase 2 small molecule terminated

    1 trial

  3. Gemcitabine , Docetaxel

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Sarcoma

    phase 2 small molecule completed

    1 trial

  4. Gemcitabine 100 mg/ml Concentrate for Solution for Infusion, 9-ING-41, Abraxane 5 mg/ml powder for dispersion for infusion.

    ACTUATE THERAPEUTICS, INC.

    Refractory Hematologic Malignancies or Solid Tumors

    phase 2 small molecule active

    1 trial

  5. Gemcitabine 38 mg/ml Concentrate for Solution for Infusion, JNJ-42756493, Gemcitabine 2 g Powder for Solution for Infusion, JNJ-42756493, JNJ-42756493, Mitomycin medac 1 mg/ml Pulver zur Herstellung einer Injektions- bzw. Infusionslösung oder einer Lösung zur intravesikalen Anwendung

    Janssen-Cilag International N.V.

    Cohort 1 and 2: High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) with FGFR Mutations or Fusions Cohort 3 Intermediate Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) with FGFR Mutations or Fusions

    phase 2 small molecule active

    1 trial

  6. Gemcitabine Accord 100 mg/ml koncentratas infuziniam tirpalui, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Padcev 30 mg powder for concentrate for solution for infusion, Zimberelimab, CARBOPLATINE MEDAC 10 mg/mL, solution à diluer pour perfusion, DOMVANALIMAB, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Bavencio 20 mg/mL concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion

    Gilead Sciences Pty Limited

    Locally Advanced/Metastatic Urothelial Cancer

    phase 2 small molecule active

    1 trial

  7. Gemcitabine Oxaliplatin 5FU and Leucovorin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pancreatic Cancer

    phase 2 small molecule active

    1 trial

  8. Gemcitabine plus Cisplatin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Biliary Tract Cancer

    phase 2 small molecule active

    1 trial

  9. Gemcitabine+simvastatin

    Samsung Bioepis NL B.V.

    Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  10. Gemcitabine/Cisplatin

    BRIGHT MINDS BIOSCIENCES INC.

    Upper Tract Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  11. Genomically Directed Monotherapy

    Vera Therapeutics

    Malignant Neoplasm of Breast

    phase 2 small molecule completed

    1 trial

  12. Gentuximab

    The First People's Hospital of Lianyungang

    Advanced Gastric or Gastroesophageal Junction Cancer

    phase 2 small molecule completed

    1 trial

  13. Gentuximab

    Changchun GeneScience Pharmaceutical Co.,

    Advanced Gastric or Gastroesophageal Junction Cancer

    phase 2 small molecule completed

    1 trial

  14. Giapreza 2.5 mg/ml concentrate for solution for infusion

    Disc Medicine

    Liver cancer (primary or secondary)

    phase 2 small molecule active

    1 trial

  15. Gilteritinib

    Astellas Pharma Inc

    Non-Small-Cell Lung Cancer

    phase 2 small molecule terminated

    1 trial

  16. Gimistotug

    BEONE MEDICINES AUS PTY LTD

    Non-Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  17. Giredestrant

    Hoffmann-La Roche

    Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

    phase 2 small molecule active

    1 trial

  18. Giredestrant

    Hoffmann-La Roche

    Early Breast Cancer

    phase 2 small molecule completed

    1 trial

  19. Givinostat 75 mg capsules, Givinostat 100 mg capsules, Givinostat 50 mg capsules

    Italfarmaco S.p.A.

    Chronic myeloproliferative neoplasm

    phase 2 small molecule active

    1 trial

  20. Glasdegib

    Jazz Pharmaceuticals Ireland Limited

    Acute Myelogenous Leukemia (AML) Due to Therapy

    phase 2 small molecule active

    1 trial

  21. Gliolan 30 mg/ml powder for oral solution.

    Photonamic GmbH & Co. KG

    Colorectal Carcinoma

    phase 2 small molecule active

    1 trial

  22. Glofitamab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Relapsed or Refractory Aggressive B-cell Lymphoma

    phase 2 small molecule active

    1 trial

  23. Glofitamab, Gazyvaro 1,000 mg concentrate for solution for infusion., MabThera 500 mg concentrate for solution for infusion, Polivy 140 mg powder for concentrate for solution for infusion.

    The George Institute

    previously untreated aggressive B-cell lymphoma

    phase 2 small molecule active

    1 trial

  24. GnP in combination with Ivonescimab and SBRT

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pancreatic Cancer

    phase 2 other active

    1 trial

  25. Green tea

    United Therapeutics Europe Ltd

    Lung Cancer Prevention

    phase 2 other completed

    1 trial

  26. Group A (FIT): Avapritinib + IA regimen

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia With T(8;21)(Q22;Q22)

    phase 2 small molecule active

    1 trial

  27. Group A：Patients with PR or ctDNA positivity after salvage treatment

    The First People's Hospital of Lianyungang

    Diffuse Large B-cell Lymphoma(DLBCL)

    phase 2 small molecule active

    1 trial

  28. HAIC + Tislelizumab +lenvatinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma (HCC)

    phase 2 other active

    1 trial

  29. HCD122

    Novartis Pharmaceuticals

    Non-Hodgkin's Lymphoma

    phase 2 small molecule completed

    1 trial

  30. HEC169096

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  31. HER3-DXd

    Daiichi Sankyo

    Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  32. HKI-272

    PUMA BIOTECHNOLOGY, INC.

    Carcinoma, Non-Small-Cell Lung

    phase 2 small molecule completed

    1 trial

  33. HKI-272

    PUMA BIOTECHNOLOGY, INC.

    Advanced Breast Cancer

    phase 2 small molecule completed

    2 trials

  34. HKI-272

    PUMA BIOTECHNOLOGY, INC.

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  35. HRS-4642+AG+Nimotuzumab

    Zhejiang University

    Borderline Resectable Pancreatic Adenocarcinoma

    phase 2 small molecule active

    1 trial

  36. HRS-6213

    Jian Li

    Patients With Solid Tumors

    phase 2 small molecule active

    1 trial

  37. HRS-7058

    Shandong Suncadia Medicine Co.,

    Pancreatic Cancer

    phase 2 small molecule active

    1 trial

  38. HYCAMTIN 4 mg powder for concentrate for solution for infusion, TAXOL 6 mg/ml, concentrato per soluzione per infusione., Neulasta 6 mg solution for injection, Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion, GEMZAR 1000 mg, poudre pour solution pour perfusion

    SUTRO BIOPHARMA, INC.

    Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal cancers)

    phase 2 small molecule active

    1 trial

  39. HYDROCORTISONE, PREDNISOLONE ACETATE PH. EUR., ASCIMINIB HYDROCHLORIDE, CYTARABINE, DEXAMETHASONE, BLINATUMOMAB, Asciminib, METHOTREXATE, DBL methotrexate injection, VINCRISTINE SULFATE, DEXAMETHASONE SODIUM PHOSPHATE

    Novartis Pharmaceuticals

    relapsed or refractory BCR::ABL1-positive (Philadelphia positive, Ph+) or BCR::ABL1-like (Ph-like) acute lymphoblastic leukemia (ALL)

    phase 2 small molecule active

    1 trial

  40. Herceptin 150 mg powder for concentrate for solution for infusion, Enhertu 100 mg powder for concentrate for solution for infusion, Fluorouracil Injection, 50 mg/ml, solution for injection, Ziihera 300 mg powder for concentrate for solution for infusion., Kadcyla 160 mg powder for concentrate for solution for infusion., Calciumfolinat Kabi 10 mg/ml Injektions-/Infusionslösung, Oxaliplatin Hikma 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Xeloda 500 mg film-coated tablets, Xeloda 150 mg film-co

    Boehringer Ingelheim

    gastroesophageal junction adenocarcinoma, metastatic gastric adenocarcinoma, metastatic breast cancer, metastatic colorectal cancer, esophageal adenocarcinoma

    phase 2 small molecule active

    1 trial

  41. Herzuma

    Vera Therapeutics

    HER2 Enriched Subtype Breast Cancer, Herzuma, PAM50 Study

    phase 2 small molecule active

    1 trial

  42. High-Low Dose Radiotherapy

    Jian Li

    Nasopharyngeal Carcinoma (NPC)

    phase 2 other active

    1 trial

  43. Homoharringtonine

    Teva Pharma GmbH

    Myeloid Leukemia, Chronic

    phase 2 small molecule terminated

    1 trial

  44. HuMax-TF-ADC, CARBOPLATIN , PEMBROLIZUMAB , BEVACIZUMAB

    Genmab A/S

    Recurrent or stage IVB cervical cancer

    phase 2 small molecule active

    1 trial

  45. Humanized CD7 CAR-T cells

    The First People's Hospital of Lianyungang

    T Lymphoblastic Leukemia/Lymphoma

    phase 2 mab active

    1 trial

  46. Humanized immunoglobulin G1 (IgG1) kappa monoclonal antibody (mAb) targeting PAUF

    Lacuna Pharma Pty Ltd

    Advanced and/or metastatic pancreatic adenocarcinoma

    phase 2 small molecule active

    1 trial

  47. Hydrogen Peroxide

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 2 small molecule active

    1 trial

  48. Hyperpolarized 13C-Pyruvate injection

    Hospital Authority, Hong Kong

    Gynecologic Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology Phase II programs exist?

2,640 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.